11/16/2026 | Press release | Distributed by Public on 11/16/2026 20:06
|
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
|
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (Right to Buy) | $5 | 11/16/2026 | M | 10,000 | (5) | 02/14/2027(6) | Common Stock | 10,000 | $ 0 | 0 | D | ||||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
|
Guiheen Lawrence P. C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 RAMSEY, NJ 07446 |
X | |||
| /s/ Lawrence P. Guiheen, by Michael A. Goldstein as Attorney-in-fact | 11/16/2026 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | The price reported in Column 4 is the price at which the shares were sold. |
| (2) | Includes, as of the transaction date, (i) 5,345 unvested restricted stock units ("RSUs") granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date and that will be settled into common stock upon vesting; and (ii) 58,254 shares of common stock owned by the Reporting Person. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| (3) | These shares are held in the Lawrence P Guiheen Revocable Trust DTD 9/20/19, over which the Reporting Person retains control. |
| (4) | These shares are held in the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE ("Guiheen Irrevocable Trust"), over which the Reporting Person retains control. The Reporting Person disclaims beneficial ownership of the securities held by the Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| (5) | The option was granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019. |
| (6) | The option terminates on the earlier of (i) February 14, 2027 and (ii) the one-year anniversary of the Reporting Person's ceasing to serve as a director of the Issuer. The Reporting Person is exercising this option due, in part, to its near-term expiration date. |